This province's medical insurance plans to add 7 new diseases! There are rare diseases that can be reimbursed more than 200,000 yuan per year

【Pharmaceutical Network Industry News】In order to better protect the outpatient needs of insured persons with chronic diseases, the Anhui Provincial Medical Insurance Bureau recently issued a notice on adjusting the catalogue of chronic diseases and outpatient drugs in outpatient outpatient medical insurance (draft for comments) to solicit public opinions, and intends to add 7 diseases such as Fabre disease, thyroxine amyloidosis cardiomyopathy, Huntington's disease, spinal cord oblongate muscle atrophy (Kennedy disease), progressive muscular dystrophy and other 7 diseases to the basic medical insurance outpatient chronic disease and outpatient drug catalog
。
Most of these 7 diseases are rare diseases, such as Fabray's disease, Huntington's disease, spinal cord oblongate muscular atrophy (Kennedy disease), progressive muscular dystrophy, optic nerve myelitis, etc.
are rare diseases
covered in the "First Rare Diseases" catalogue jointly released by the National Health Commission and other five departments in May 2018.

For a long time, rare disease people have not only faced the problem of no drugs available or less drugs, but also the problem of "sky-high" drugs, which has attracted much attention
.

From the catalogue of new diseases and annual reimbursement limits of medical insurance in Anhui Province, it can be seen that the annual reimbursement limits of many new diseases are relatively large, which will reduce the burden on patients and improve the accessibility of
drugs.

For example, Fabre disease, according to the annual reimbursement limit of resident medical insurance exceeds 200,000 yuan, reaching 224,000 yuan, and the annual reimbursement limit of employee medical insurance is higher, reaching 256,000 yuan
.

Fabre disease (FD) is an X-linked hereditary lysosomal storage disease in which patients are clinically multi-organic, multisystemic and may develop
as a result of age.

At present, the number of domestic FD patients is still increasing, and as of May 2022, the number of confirmed patients in China is 555
.

At present, the domestic drug for the indications of Fabre disease, there has been a national medical insurance directory, that is, Takeda's agatase α injection of concentrated solution (trade name: Ruipujia), the drug previously cost as high as one million yuan, through the 2021 national medical insurance negotiations, the drug successfully entered after the price reduction, the cost of a single drug for patients has been reduced to thousands of yuan
.

The Anhui Provincial Medical Insurance Bureau issued a document in the outpatient drug catalogue stating that the intensive solution of the Agatase α for injection is used for long-term enzyme replacement therapy
for patients diagnosed with Fabre disease (α-galactosidase A deficiency).

This product is suitable for adults, children and teenagers
.

In addition to Fabre disease, the annual reimbursement limit for thyroxine amyloidosis cardiomyopathy is also relatively high, all of which are more than 100,000 yuan, of which the annual reimbursement limit of employee medical insurance can reach 164,000 yuan
.

This type of rare disease is a type of cardiac amyloidosis, which is mainly caused by abnormal protein deposition in the myocardial stroma, due to multisystem disease involving diseases, poor
clinical specificity.

The outpatient drug catalogue shows that the variety of related therapeutic drugs for this type of disease is relatively rich, with a total of 14, including clobenzazole acid softgels, dabigatran ester, rivaroxaban, empagliflozin, etc
.

For another example, the annual reimbursement limit of resident medical insurance for the three new diseases of Huntington's disease, spinal cord oblongatoril muscular dystrophy (Kennedy disease), and optic neuromyelitis is more than 20,000 yuan, and the annual reimbursement limit of employee medical insurance is more than 20,000 yuan, or even more than 30,000 yuan
.

As more rare disease drugs are implemented into local medical insurance, it will bring good news
to local insured patients.

The Anhui Provincial Medical Insurance Bureau requires that the basic medical insurance for employees and urban and rural residents in the province uniformly implement the catalogue of new diseases, identification standards, and medication catalogs, and each coordinating region must not adjust
it by itself.

The Provincial Medical Insurance Bureau dynamically adjusts the catalogue according to the changes in the national medical insurance drug catalog, the affordability of the medical insurance fund and the actual clinical diagnosis and treatment of diseases
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.